



REMARKS

Submitted herewith, as Appendix A, on a separate sheet, according to the provisions of 37 CFR 1.21(b)(1)(iii), is a version of the above replacement paragraph, marked up to show all the changes relative to the previous version of the paragraph.

No fee is believed necessary in connection with filing this Supplemental Preliminary Amendment. However, if any fee is determined necessary for filing this Preliminary Amendment authorization is hereby given to charge such fee to Deposit Account No. 16-1445.

Respectfully submitted,

Date: September 21, 2001

Kristina L. Konstas
Kristina L. Konstas
Attorney for Applicant(s)
Reg. No. 37,864

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-6380



Patent Application
Attorney Docket No. PC10825A

Application Serial No. 09/919,630
Filed: July 31, 2001

APPENDIX A

The paragraph on page 1, starting at line 3, of the above-identified application is amended as follows:

Marked-up Copy, Do Not Enter:

This application claims the benefit under 35 U.S.C. 119 (e) of U.S. Provisional Patent Application No. 60/221,724, filed July 31, 2000; U.S. Provisional Patent Application No. 60/228,394, filed August 28, 2000; and U.S. Provisional Patent Application No. ~~60/228,437~~ 60/229,437, filed August 31, 2000.